Sun Pharma

Sun Pharma has agreed to acquire 14 established prescription brands from Novartis in Japan in a deal valued at $293m.

As per the agreed terms, the company will acquire products that have combined annualised revenues of around $160m. These products are said to address medical conditions across several therapeutic areas.

With this acquisition, Sun Pharma will enter the Japanese pharmaceutical market estimated at $73bn, accounting for more than 7% of the $1tn global pharmaceutical market.

“This acquisition marks Sun Pharma’s foray into the Japanese prescription market.”

Sun Pharma managing director Dilip Shanghvi said: "Japan is a market of strategic interest for us. This acquisition marks Sun Pharma’s foray into the Japanese prescription market and provides us an opportunity to build a larger product portfolio in the future."

Novartis will, however, continue to distribute these brands, for a certain period, pending transfer of all marketing authorisations to Sun Pharma’s subsidiary.

The acquired brands will be marketed by a reliable and established local marketing partner under the Sun Pharma label. The marketing partner will also be responsible for distribution of the brands.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In September last year, Sun Pharm agreed to acquire US eye care firm InSite Vision as part of a $48m deal.

InSite Vision is focused on developing new specialty ophthalmic products, including three late-stage programmes and the acquisition will help Sun Pharma, which is in the process of establishing a branded ophthalmic business in the US.

Sun Pharma currently operates 49 manufacturing facilities across six continents, R&D centres across the globe.

Image: Sun Pharma’s global presence is supported by 49 manufacturing facilities across six continents. Photo: courtesy of Sun Pharmaceutical Industries.